In a phase 3 trial of 202 adults with core-binding factor AML, adding dasatinib to intensive chemotherapy did not improve event-free survival (HR 0.92; P=.66) or secondary outcomes, and serious adverse events were more common (64% vs 36%).
RCTn = 202
Döhner et al. A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia